Intestifalk Uno

Budesonide, the active ingredient in Intestifalk Uno, is a Glucocorticoid presented as an oral formulation for oral use. It is employed to reduce intestinal inflammation in patients with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. It is formulated for targeted release in the gastrointestinal tract, allowing high local activity with limited systemic exposure.

GNH USA supplies Intestifalk Uno as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies, transplant centres and specialty clinics worldwide, adhering to stringent quality standards and regulatory requirements.

Budesonide is a glucocorticoid used to modulate inflammatory pathways in the gastrointestinal tract.

Crohn's disease: reduces intestinal inflammation and helps achieve remission. Ulcerative colitis: decreases mucosal inflammation and improves symptom control. Induction of remission in IBD: facilitates the transition from active disease to a quiescent state.

Common Side Effects: - Oral thrush: fungal infection of the mouth. - Nausea: feeling of sickness or upset stomach. - Headache: mild to moderate head pain. - Abdominal pain: discomfort in the stomach area. - Dyspepsia: indigestion or heartburn. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Severe infection: heightened risk of bacterial, viral, or fungal infections. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Osteoporosis: loss of bone density with long‑term use. - Cataracts: clouding of the eye lens. - Growth retardation: impaired growth in pediatric patients.

Intestifalk Uno should be prescribed after careful assessment of disease severity and patient history.

Assess disease severity before initiation: ensure appropriate indication. Monitor for adrenal insufficiency: watch for signs of cortisol deficiency. Avoid abrupt discontinuation: taper dosage under medical supervision. Use cautiously in patients with active infections: risk of worsening infection. Evaluate bone health during long‑term therapy: consider calcium/vitamin D supplementation. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Budesonide may interact with other medicines that affect its metabolism or increase infection risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Potent enzyme inducers (e.g., rifampicin): may reduce therapeutic effect. - Systemic immunosuppressants (e.g., cyclosporine): heightened immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may alter clotting parameters. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal irritation. - Live vaccines: reduced vaccine efficacy and possible infection.